{"id":"W4224433803","doi":"10.1016/s1474-4422(22)00143-0","title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Natalizumab; Medicine; Progressive multifocal leukoencephalopathy; Multiple sclerosis; Clinical endpoint; Dosing; Relapsing remitting; Randomized controlled trial; Neurology; Pediatrics; Physical therapy; Internal medicine; Immunology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000880164,0.0002676966,0.001786154,0.0002296531,0.000246314,0.00003178098,0.0004234335,0.00007909522,0.0000309822],"category_scores_gemma":[0.0007349597,0.000174228,0.00008372062,0.0005373431,0.0001476343,0.0001092135,0.0003172702,0.0007455033,9.551879e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005819556,"about_ca_system_score_gemma":0.0001262921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004304806,"about_ca_topic_score_gemma":0.00006362161,"domain_scores_codex":[0.9970528,0.0006288253,0.0008943511,0.0004313169,0.0004690243,0.0005236785],"domain_scores_gemma":[0.9969459,0.001537369,0.0008254555,0.0004703708,0.0001055772,0.0001152916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9587269,0.004098898,0.02206038,0.00004285254,0.0002978007,0.00003728024,0.002070718,0.001919943,0.005891688,0.00002047567,0.0000819938,0.004751033],"study_design_scores_gemma":[0.9666233,0.02249547,0.004202408,0.0004222401,0.0005750632,0.0000132438,0.0004037647,0.004242523,0.0007351791,0.000006362826,0.00008213503,0.0001983288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944258,0.0005016142,0.00007745652,0.000584471,0.0005053849,0.003576733,0.00004455151,0.00003719748,0.0002467816],"genre_scores_gemma":[0.9989027,0.00001030663,0.0003150517,0.0004647822,0.00008124461,0.0001376325,0.0000293637,0.00005062778,0.00000832216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01839658,"threshold_uncertainty_score":0.7104813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09327933621658352,"score_gpt":0.3429768786919041,"score_spread":0.2496975424753206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}